[
  {
    "ts": null,
    "headline": "Why the Market Dipped But Amgen (AMGN) Gained Today",
    "summary": "Amgen (AMGN) concluded the recent trading session at $318.65, signifying a +0.47% move from its prior day's close.",
    "url": "https://finnhub.io/api/news?id=8c874c90529e381c534223c4e583cea542e260cd85228778254eb212270f5578",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742334616,
      "headline": "Why the Market Dipped But Amgen (AMGN) Gained Today",
      "id": 133325060,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) concluded the recent trading session at $318.65, signifying a +0.47% move from its prior day's close.",
      "url": "https://finnhub.io/api/news?id=8c874c90529e381c534223c4e583cea542e260cd85228778254eb212270f5578"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?",
    "summary": "AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.",
    "url": "https://finnhub.io/api/news?id=edcc5e001a1947ec8ec0ac6af5efba0d73bd69847c412e40bddc011ea0042775",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742312940,
      "headline": "Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?",
      "id": 133325061,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.",
      "url": "https://finnhub.io/api/news?id=edcc5e001a1947ec8ec0ac6af5efba0d73bd69847c412e40bddc011ea0042775"
    }
  },
  {
    "ts": null,
    "headline": "Prediction: These 2 Stocks Will Outperform the Market Through 2030",
    "summary": "The more we extend our horizon, the more likely it is that stocks will provide juicy returns.  Leading drugmaker Amgen could have several growth drivers through the end of the decade.  Tepezza remains the only treatment for TED approved in the U.S., and Amgen has also been launching it in other countries.",
    "url": "https://finnhub.io/api/news?id=f2fe6063b8313c9d93534b9c548fe38e8aaed476bd5c96097b541a07cb456c69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742305980,
      "headline": "Prediction: These 2 Stocks Will Outperform the Market Through 2030",
      "id": 133324996,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The more we extend our horizon, the more likely it is that stocks will provide juicy returns.  Leading drugmaker Amgen could have several growth drivers through the end of the decade.  Tepezza remains the only treatment for TED approved in the U.S., and Amgen has also been launching it in other countries.",
      "url": "https://finnhub.io/api/news?id=f2fe6063b8313c9d93534b9c548fe38e8aaed476bd5c96097b541a07cb456c69"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Income: Lanny's February 2025 Summary",
    "summary": "Dividend Income: Lanny's February 2025 Summary",
    "url": "https://finnhub.io/api/news?id=96254f82b04f4fa52f3d90b4b63f1b9618a359eb435b95d2add8977c4b53ce4b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742301600,
      "headline": "Dividend Income: Lanny's February 2025 Summary",
      "id": 133230615,
      "image": "",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=96254f82b04f4fa52f3d90b4b63f1b9618a359eb435b95d2add8977c4b53ce4b"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. (AMGN): Among the Best Biotech Stocks to Buy According to Billionaires",
    "summary": "We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best biotech stocks. Although biotech stocks had a “challenging” year in 2024, JPMorgan believes that some of the industry’s companies could […]",
    "url": "https://finnhub.io/api/news?id=8f3781d34c474fc00ac2c84803d999adbb1d239354d9e6ca013af6ce9b8476c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742290469,
      "headline": "Amgen Inc. (AMGN): Among the Best Biotech Stocks to Buy According to Billionaires",
      "id": 133325063,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best biotech stocks. Although biotech stocks had a “challenging” year in 2024, JPMorgan believes that some of the industry’s companies could […]",
      "url": "https://finnhub.io/api/news?id=8f3781d34c474fc00ac2c84803d999adbb1d239354d9e6ca013af6ce9b8476c2"
    }
  }
]